Introduction
============

Breast cancer is a common condition. It is a leading cause of death among women, and its incidence increases with age. Aging of the population and improvement of the quality of life of elders make it a major public health issue.

More than 50% of patients with breast cancer are 65 years or older, and around 30% are more than 70 years old.[@b1-bctt-7-165]--[@b3-bctt-7-165] In [Table 1](#t1-bctt-7-165){ref-type="table"}, we show the incidence and the mortality of breast cancer in France.

A noncompliance with treatment, the existence of comorbidities that can affect mortality, and the high cost weighed against the expected poor benefits in this population are all factors that explain why most of the screening strategies do not include patients over 70 years of age. The result is that the diagnosis of breast cancer is often made late, and about 48% of patients over 65 years of age have metastases at the time of diagnosis.[@b4-bctt-7-165]

We performed a review of the literature to identify risk factors of breast cancer in women over 65 years old to determine the benefits and disadvantages of screening mammography in patients aged above 75 years. This review found that age is the main risk factor to develop breast cancer and die of it. This risk increases in cases of late first pregnancy, no history of breast-feeding, delayed menopause, hormonal replacement therapy, and postmenopausal overweight.

Randomized trials studying advantages of screening mammography have excluded women aged above 74 years. Thus, the benefits of screening this category of the population are unknown. However, observational studies suggest that older women with a life expectancy of more than 10 years should be included in mammography-based screening policies. These studies estimate that the mortality is reduced by 0.2% when women aged above 70 years undergo 2 yearly screening mammographies for 10 years rather than discontinuing this test at the age of 69.[@b5-bctt-7-165]

In a review by Marmot et al,[@b6-bctt-7-165] the panel encouraged breast cancer screening in the UK because it reduced breast cancer mortality by 20% in 10,000 UK women aged 50--70 years invited for screening mammography every 3 years. About 681 cancers were diagnosed and 43 deaths were prevented, but 129 represented an overdiagnosis. The choice between the benefits and harms of screening should be shared with women who agreed to be screened.[@b6-bctt-7-165]

The screening definitely has benefits such as reducing breast cancer mortality, but expert opinions are different from one country to another. Some find that the benefit is minimal, against a non-negligible overdiagnosis, which presents a source of anxiety for women.

In our opinion, the benefits and harms of screening should be discussed with women who agree to be screened and their choices should be respected.

Age does not affect histologic features of breast cancer. However, lobular, mucinous carcinomas are slightly more common in older women. These are usually small, slow-proliferating, and low-grade tumors with positive hormonal receptors, negative HER2, and normal p53.[@b7-bctt-7-165],[@b8-bctt-7-165]

Discussion
==========

Treatment of early breast cancer in older women
-----------------------------------------------

Most randomized trials did not include older women, and prospective studies in this category are scarce. Hence, the treatment of breast cancer in older patients is based on the management of younger women. Currently, for every patient over 70 years of age presenting with breast cancer, a multidimensional geriatric assessment, including an accurate history, a clinical examination, and a comprehensive biological workup, is necessary to assess the patient's nutritional state; their mental, psychological, physical, and social autonomy; their independence; and their comorbidities, and thus to adapt the management.[@b9-bctt-7-165]

Recently, Audisio and Wyld[@b10-bctt-7-165] reported that treatment of breast cancer in older women is not standard. In this editorial they discuss the choice between primary endocrine therapy and surgery for older women with breast cancer ER+ (estrogen receptor-positive). Four factors should be taken into consideration: anesthesiological contraindications; surgeon's preference; patient's preference; input from family, carers and friends. But, Audisio and Wyld[@b10-bctt-7-165] concluded that none of these factors is robust enough to make a decision.

Surgery
-------

Regardless of age, the treatment must aim for the best efficiency. Whenever possible, the management of breast cancer in older women should be similar to that in younger patients. Advanced age in itself should not be a limitation to treatment.

There are no standard guidelines set for older patients, and the management is different from one country to another and from one center to another. An international study comparing local treatments (surgery and radiotherapy) for operable breast cancer in older women included 204,885 patients across different countries. In many countries, most patients had undergone conservative surgery, with the highest proportion in Switzerland. The most striking conclusion drawn was that a large number of patients did not undergo any surgical intervention and that the likelihood to benefit from surgery for breast cancer diminished with increasing age. In all countries, an advancing age was also associated with less radiotherapy after tumorectomy. Moreover, older women treated for breast cancer underwent less axillary dissections. This study showed that despite large differences in managing older women with breast cancer, the survival was similar across all countries.[@b11-bctt-7-165]

Over the last 2 decades, studies were conducted with the aim of determining advantages and disadvantages of surgery and neoadjuvant hormonal therapy ([Table 2](#t2-bctt-7-165){ref-type="table"}).[@b12-bctt-7-165]--[@b21-bctt-7-165] Two randomized controlled trials[@b12-bctt-7-165],[@b13-bctt-7-165] showed better locoregional control in favor of the surgical group, although results were not statistically significant. However, there was no survival benefit in either the tamoxifen-only or the surgery-only group. Similar results have been obtained by the Cancer Research Campaign UK when it compared tamoxifen only, to surgery followed by tamoxifen, in women aged 70 years or over with operable breast cancer.[@b16-bctt-7-165] The Greta study compared tamoxifen as a primary treatment for operable breast cancer, with surgery followed by adjuvant tamoxifen, in women over 70 years of age and showed no difference in terms of survival.[@b15-bctt-7-165]

Recently, a Cochrane review conducted by Hind et al[@b17-bctt-7-165] assessed the clinical efficacy of hormonal treatment as the sole treatment in operable breast cancer in women aged 70 years or above. No significant difference could be shown between primary hormonal therapy and surgery in terms of mortality. However, this review did demonstrate a longer survival without progression in favor of surgery, with or without hormonal therapy.[@b17-bctt-7-165] Although surgical management seems to offer better local control, primary hormonal therapy can be an alternative for women with breast cancer expressing estrogen receptors and for whom surgery is not an option, either because of refusal or contraindication.[@b17-bctt-7-165],[@b18-bctt-7-165]

Axillary lymph nodes dissection
-------------------------------

In patients with breast cancer, the spread to axillary lymph nodes is a major prognostic factor that affects the therapeutic management.[@b22-bctt-7-165] Axillary lymph nodes dissection (ALND) has minimal curative role, and its potential advantages are largely debated. While some studies show longer survival for patients undergoing axillary dissection,[@b23-bctt-7-165] others failed to show any benefit.[@b24-bctt-7-165]

The American College of Surgeons Oncology Group (ACOSOG, Durham, NC, USA) conducted a prospective randomized trial, Z11, comparing axillary dissection vs no axillary surgery in women with T1 and T2 invasive breast cancer and 1--2 sentinel lymph node (SLNs), all undergoing lumpectomy and tangential whole-breast irradiation. The Z11 trial showed no significant difference in locoregional recurrence, after a median follow-up of 6.3 years. The risk of cancer recurring in the lymph nodes was 0.4% in groups who had the surgery and 0.9% in groups without axillary dissection, with less morbidity. There was no survival difference between the two groups.[@b25-bctt-7-165]

ALND may also be a cause of morbidity in older women (lymphedema, parethesias, adhesive capsulitis, etc) or may worsen a preexisting disability.[@b26-bctt-7-165] In order to reduce the number of patients undergoing unnecessary ALND, axillary ultrasound and fine-needle aspiration of suspicious lymph nodes are usually performed preoperatively. When negative, sentinel lymph node technique seems to be a promising option to rule out any metastases.[@b27-bctt-7-165]

Adjuvant chemotherapy
---------------------

Older patients with breast cancers were often excluded from clinical trials. An Oxford review of literature[@b28-bctt-7-165] showed that polychemotherapy presents significant benefits in terms of survival and remission for patients younger than 70 years. However, these advantageous effects seem to diminish with increasing age.[@b28-bctt-7-165]

Unfortunately, only 600 women aged 70 years or above were included in the 47 analyzed trials of adjuvant chemotherapy, which makes estimating benefits of chemotherapy in this category impossible.[@b29-bctt-7-165] Many patients with breast cancer are 70 years old or older, and with the aging of the population, it is expected that their numbers will increase even more.[@b28-bctt-7-165]

Consequently, there is obviously an urgent need to evaluate adjuvant chemotherapy in older patients. Adjuvant chemotherapy has been shown to be consistently beneficial only for younger patients. In a meta-analysis, adjuvant chemotherapy improved overall survival in patients aged between 50 and 69 years of age, regardless of the estrogen receptor status.[@b30-bctt-7-165] However, because of the small number of patients over 70 years of age (n=1,200) and the heterogeneity of both the disease and treatments, no definitive conclusions could be drawn.

In addition, two large observational studies suggested that adjuvant chemotherapy could be of benefit only to patients over 65 years of age with estrogen receptor negative and positive lymph nodes.[@b31-bctt-7-165],[@b32-bctt-7-165] Muss et al[@b33-bctt-7-165] conducted a randomized controlled trial with the aim of demonstrating the noninferiority of capecitabine to standard chemotherapy (CMF: cyclophosphamide, methotrexate and fluorouracil or AC: doxorubicin and cyclophosphamide) in women over 65 years of age with breast cancer. The results showed that capecitabine was inferior to standard chemotherapy in terms of relapse-free survival (3 years survival without relapse of 68% vs 85%; HR: 2.09, *P*\<0.001) and overall survival (3 years overall survival 86% vs 91%; HR: 1.85, *P*=0.02). The subgroup analysis revealed a significant interaction between treatment and hormonal status. Standard chemotherapy was demonstrated to be superior to capecitabine in terms of overall survival only in patients with negative estrogen receptors.[@b33-bctt-7-165],[@b34-bctt-7-165]

Radiotherapy
------------

The proportion of older patients receiving adjuvant radiotherapy is increasing. Likewise, the number of patients undergoing conservative mammary surgery with no irradiation is increasing. Again, as older patients tend to be excluded from randomized trials, the database that includes patients receiving locoregional treatment is limited.[@b35-bctt-7-165] In 2011, the Oxford review showed that adjuvant radiotherapy after conservative mammary surgery halves the risk of a first relapse in all age groups; although, the absolute benefit in "low-risk" older patients seems to be minimal. Recently, Hughes et al[@b36-bctt-7-165] reported the results of the Cancer and Leukemia Group (CALGB, Leicester, UK), who reviewed 9,343 studies on the impact of radiotherapy in women aged over 70 years with breast cancer. In the group treated with radiotherapy and tamoxifen, the rate of survival with no locoregional relapse was 98% vs 90% in patients receiving tamoxifen only (*P*\<0.001), with no significant difference in overall survival. Following these results, treatment with tamoxifen only seems a reasonable alternative for these patients.[@b36-bctt-7-165]

Adjuvant hormonal therapy
-------------------------

Although only few data that include women aged over 70--75 years are available, adjuvant hormonal therapy is a reference treatment for postmenopausal women with hormone-receptor-positive breast cancer. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis, which included 3,700 women, confirmed that tamoxifen reduced the relapse rate by 28% and mortality by 21% in women aged 70 years or more. Nevertheless, it is important to note that among the patients included, there were only 726 women aged above 70 years who received tamoxifen over 2 years, with a reduction of annual risk of relapse of 42%±8%, and 186 patients who received it during 5 years, reducing the annual risk of relapse by 54%±13%.[@b37-bctt-7-165] The reduction of the annual risk of mortality was 36%±7% and 34%±13%, respectively. This difference was statistically not significant, and, consequently, the effect of tamoxifen in this category of age did not seem to be related to the duration of treatment. However, the small number of the specimens refrain us from drawing any conclusion. [Table 3](#t3-bctt-7-165){ref-type="table"}[@b38-bctt-7-165]--[@b41-bctt-7-165] shows the different studies comparing adjuvant hormonal therapy with tamoxifen vs placebo in older patients. The Breast International Group (BIG, Brussels, Belgium) 1-98 is a Phase III randomized double-blind study comparing four protocols of hormonal treatment over 5 years in postmenopausal women with hormone-receptor-positive breast cancer (group 1: letrozole only, group 2: letrozole followed by tamoxifen, group 3: tamoxifen only, group 4: tamoxifen followed by letrozole). A total of 8,010 women were assessed after a median followup of 25.8 months, and 351 events occurred in the letrozole group and 428 occurred in the tamoxifen group. At 5 years, the disease-free survival rate reached 84% in the letrozole group and 81.4% in the tamoxifen group. Complications, which included venous thromboembolic complications, endometrial cancers, and vaginal bleeding, were more common in the tamoxifen group. On the other hand, women receiving letrozole suffered more hypercholesterolemia, cardiac events, and bone fractures.[@b42-bctt-7-165] The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, which compared anastrozole and tamoxifen in women over 65 years of age, with a small proportion of patients who were over 70 years, just 27% were included, revealed a benefit in favor of anastrozole by reducing recurrence at 9.7% in anastrazole arms vs 12.5% in tamoxifen arms at 5 years, but no effect of overall survival (OS) was noted. In the subgroup analysis, the advantage of anastrozole was mainly observed in patients who had not received any adjuvant chemotherapy and in those who had lymph node involvement, whereas in the BIG 1-98 trial, letrozole was more beneficial in patients having received chemotherapy and in those with lymph node metastasis.[@b43-bctt-7-165]

Anti-HER2 therapy
-----------------

The prevalence of tumors overexpressing HER2 in women aged 70 years or more varies between 7% and 20%. Up to now, data regarding efficacy and tolerance of trastuzumab in older patients are still scarce. Some retrospective series suggest that tolerance to trastuzumab is maintained in patients over 60 years of age.[@b44-bctt-7-165]--[@b46-bctt-7-165] However, adjuvant trastuzumab trials revealed that the incidence of cardiac events increased with age and close cardiac follow-up is required. In addition, a recent Spanish retrospective study, which analyzed 45 patients over 70 years of age with locally advanced breast cancer who received trastuzumab, found that cardiac toxicity was more likely in patients with background of heart disease and/or diabetes.[@b47-bctt-7-165] Finally, a cohort study that followed 9,535 patients with a median age of 70 years found that among the 2,203 patients who received trastuzumab, 29.4% developed congestive heart failure vs 18.9% for other patients (*P*\<0.001).[@b48-bctt-7-165]

Conclusion
==========

Breast cancer is common in older women. This population requires particular and adapted management, hence the importance of informing practitioners about the necessity of a thorough geriatric assessment prior to any medical prescription. Importantly, integrating geriatric tools in prospective studies would allow a better understanding of tolerance and observance aspects related to different treatments.
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###### 

The incidence and the mortality of breast cancer in France

  Age (years)   Incidence/100,000   Mortality/100,000
  ------------- ------------------- -------------------
  60--64        299.8               61.3
  65--69        386.1               73.4
  70--74        341.8               84.6
  75--79        295.8               101.2
  80--84        304.4               132.6
  85--89        338                 183
  90--94        283.6               273.9
  \>95          255.3               309.9

###### 

Summary of different studies comparing surgery ± hormonal therapy in older women

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name of study                                         Number of patients included   Study design                                                         Median duration of survival (years)   Progression-free survival                                          Overall survival
  ----------------------------------------------------- ----------------------------- -------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------
  EORTC 10851 (UK) (Fentiman et al[@b14-bctt-7-165])    164                           Surgery vs tamoxifen 20 mg/d                                         10                                    63/82 vs 69/82[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\         60/82 vs 50/82[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                 HR: 0.55                                                           HR: 1.11 (0.75--1.65)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}

  Nottingham (UK) (Robertson et al[@b12-bctt-7-165])    131                           Surgery vs tamoxifen 40 mg/d                                         5                                     56/65 vs 57/66[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\         28/65 vs 28/66[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                 HR: not estimated                                                  HR: 1.06 (0.59--1.92)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}

  St Georges (UK) (Gazet et al[@b13-bctt-7-165])        200                           Surgery vs tamoxifen 20 mg/j                                         6                                     60/100 vs 70/100[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\       28/100 vs 33/100[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                 HR: not estimated                                                  HR: 0.75 (0.44--1.26)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}

  CRC (UK) (Fennessey et al[@b20-bctt-7-165])           455                           Surgery plus tamoxifen 40 mg/j vs tamoxifen only                     13                                    Not reported                                                       159/225 vs 187/230[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                    HR: 0.78 (0.63--0.96)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}

  GRETA (Italy) (Mustacchi et al[@b15-bctt-7-165])      274                           Surgery plus radiotherapy plus tamoxifen 20 mg/d vs tamoxifen only   7                                     140/239 vs 188/235[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\     130/239 vs 144/235[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                 HR: 0.65 (0.53--0.81)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}   HR: 0.98 (0.77--1.25)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}

  Naples (Italy) (Capasso et al[@b21-bctt-7-165])       75                            Surgery plus radiotherapy plus tamoxifen\                            10                                    9/38 vs 13/37[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\          121 months vs 123 months\
                                                                                      20 mg/d vs tamoxifen only 160 mg/d then 20 mg/d until progression                                          *P*=0.4594                                                         *P*=0.8

  Nottingham.2 (UK) (Willsher et al[@b19-bctt-7-165])   147                           Surgery plus tamoxifen vs tamoxifen 20 mg/j                          5                                     Not reported                                                       8/53 vs 14/94[\#](#tfn1-bctt-7-165){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                    HR: 0.80 (0.73--2.32)[\$](#tfn2-bctt-7-165){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Number of patients who have progressed by the total number of patients included in each arms of the study;

data are expressed in months, and values in parentheses indicate the confidence interval of hazard ratio.

**Abbreviation:** HR, hazard ratio; d, day.

###### 

Summary of different studies comparing adjuvant hormonal therapy with tamoxifen vs placebo in older women

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name of study                       Study design                                                                                                          Median duration of follow-up   Progression-free survival                              Overall survival
  ----------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------
  Castiglone et al[@b38-bctt-7-165]   the study included 320 patients aged between 66 and 80 years. They received Tamoxifen 20mg/day and prednisone         96 months                      36% vs 22%\                                            49% vs 42%\
                                                                                                                                                                                           *P*=0.004                                              *P*=0.43

  Crivellari et al[@b41-bctt-7-165]   349 patients included aged between 66 and 80 years. Mastectomy followed by tamoxifen and prednisone vs no treatment   21 years                       Improvement of progression free survival (*P*=0.003)   Improvement of 15 years overall survival and relapse-free survival, 10%±3% vs 19%±3%\
                                                                                                                                                                                                                                                  HR, 0.71;[\$](#tfn4-bctt-7-165){ref-type="table-fn"} 95% CI, 0.58 to 0.86[\$](#tfn4-bctt-7-165){ref-type="table-fn"}

  Mouridsen et al[@b40-bctt-7-165]    509 patients included were 70 years old or more tamoxifen and local irradiation vs irradiation only                   6 years                        48% vs 39%\                                            No difference in overall survival
                                                                                                                                                                                           *P*=0.0008                                             

  Cummings et al[@b39-bctt-7-165]     181 patients included were 65--84 years old tamoxifen over 2 years vs placebo                                         10 years                       7.4 vs 4.4 years\                                      8.5 vs 8 years\
                                                                                                                                                                                           *P*=0.001                                              *P*=0.063
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Data are expressed in months.

**Abbreviations:** CI, confidence interval; HR, hazard ratio.
